Gilead Sciences Inc (GILD)
66.74
+0.58
(+0.88%)
USD |
NASDAQ |
Apr 19, 16:00
66.77
+0.03
(+0.04%)
After-Hours: 16:00
Gilead Sciences Research and Development Expense (TTM): 5.719B for Dec. 31, 2023
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 5.719B |
| September 30, 2023 | 3.159B |
| June 30, 2023 | 2.851B |
| March 31, 2023 | 2.546B |
| December 31, 2022 | 4.977B |
| September 30, 2022 | 7.487B |
| June 30, 2022 | 7.439B |
| March 31, 2022 | 7.429B |
| December 31, 2021 | 4.606B |
| September 30, 2021 | 4.826B |
| June 30, 2021 | 4.883B |
| March 31, 2021 | 5.09B |
| December 31, 2020 | 5.039B |
| September 30, 2020 | 4.56B |
| June 30, 2020 | 4.432B |
| March 31, 2020 | 4.128B |
| December 31, 2019 | 4.181B |
| September 30, 2019 | 3.934B |
| June 30, 2019 | 3.843B |
| March 31, 2019 | 4.04B |
| December 31, 2018 | 3.92B |
| September 30, 2018 | 4.218B |
| June 30, 2018 | 4.068B |
| March 31, 2018 | 3.74B |
| December 31, 2017 | 3.734B |
| Date | Value |
|---|---|
| September 30, 2017 | 3.792B |
| June 30, 2017 | 4.144B |
| March 31, 2017 | 4.764B |
| December 31, 2016 | 5.098B |
| September 30, 2016 | 4.647B |
| June 30, 2016 | 4.249B |
| March 31, 2016 | 3.583B |
| December 31, 2015 | 3.014B |
| September 30, 2015 | 3.302B |
| June 30, 2015 | 3.189B |
| March 31, 2015 | 2.955B |
| December 31, 2014 | 2.854B |
| September 30, 2014 | 2.361B |
| June 30, 2014 | 2.277B |
| March 31, 2014 | 2.217B |
| December 31, 2013 | 2.12B |
| September 30, 2013 | 2.007B |
| June 30, 2013 | 1.927B |
| March 31, 2013 | 1.799B |
| December 31, 2012 | 1.76B |
| September 30, 2012 | 1.723B |
| June 30, 2012 | 1.547B |
| March 31, 2012 | 1.433B |
| December 31, 2011 | 1.229B |
| September 30, 2011 | 1.220B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
2.546B
Minimum
Mar 2023
7.487B
Maximum
Sep 2022
4.796B
Average
4.606B
Median
Dec 2021
Research and Development Expense (TTM) Benchmarks
| Amgen Inc | 4.784B |
| Johnson & Johnson | 15.30B |
| Eli Lilly and Co | 9.313B |
| CymaBay Therapeutics Inc (DELISTED) | 80.80M |
| Arcus Biosciences Inc | 340.00M |